

SKYEPHARMA PLC
Form 6-K
March 04, 2005

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2005

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

4 March 2005

SkyePharma PLC

PAXIL CR CLARIFICATION

LONDON, UK, 4 March 2005 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) notes the announcement today by GlaxoSmithKline ("GSK") concerning the halting of the US distribution of Paxil CR, a treatment for depression and several anxiety disorders. GSK stated that the halt in distribution results from manufacturing issues which do not pose a health risk to patients. The FDA is advising that patients taking Paxil CR should continue taking their tablets and talk with their healthcare provider if they have questions. GSK is working with the FDA to resolve these issues as quickly as possible.

SkyePharma provided the formulation of Paxil CR, but has no involvement in its manufacturing.

About SkyePharma PLC

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now ten approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit www.skyepharma.com

For further information please contact:

SkyePharma PLC

Michael Ashton, Chief Executive Officer
Peter Laing, Director of Corporate Communications
Sandra Haughton, US Investor Relations

+44 207 491 1777

**+44 207 491 5124
+1 212 753 5780**

Buchanan Communications

Tim Anderson / Rebecca Skye Dietrich

+44 207 466 5000

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: March 4, 2005